Compare iShares MSCI China ETF (MCHI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI China ETF trades at $54.17, while Summit Therapeutics Inc trades at $14.29 (market cap $10.48B). The key difference: iShares MSCI China ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MCHI | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $29.32 |
52-Week Low | $50.48 | $13.05 |
Market Cap | — | $10.48B |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights China's economic stimulus focus and AI sector growth, which could impact this China-focused ETF. Dividend activity is scheduled for mid-2026.
The outlook is cautious due to bearish technicals and macroeconomic risks from U.S.-China tensions, though AI-driven exports offer growth potential. Investors face value trap risks amid mixed analyst sentiment, requiring close monitoring of China's policy developments and corporate earnings for directional cues.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
